Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 41, pages 355–361 (2008)Cite this article

Abstract

Allogeneic SCT is an effective therapy for lymphoma. Reduced-intensity conditioning (RIC) reduces non-relapse mortality (NRM) associated with myeloablative conditioning but relapse rates are high when performed in active disease. This study was designed to explore the safety and outcome of ibritumomab tiuxetan (Zevalin) combined with RIC in patients with advanced lymphoma. The study included 12 patients, median age 54 years (37–62), with a median of four prior treatments (2–6) and active disease documented on PET–CT. Zevalin 0.4 mCi/kg was given on day −14 and fludarabine combined with BU (n=6) or melphalan (n=6) was started on day −6. GVHD prevention was tapered 3 months after SCT to augment the graft-versus-lymphoma effect. All patients engrafted, a median of 14 days after SCT. Eighty-three percent achieved CR/PR. With a median follow-up of 21 months (12–37), 2-year PFS is 33%. Only three patients relapsed; cumulative incidence 25%. NRM was 42%, predominantly due to acute GVHD. Zevalin–RIC is feasible with consistent engraftment, acceptable organ toxicity, but high rates of acute GVHD. The low incidence of relapse suggests augmented anti-lymphoma effect. Zevalin–RIC merits further study. Better results may be achieved in patients earlier in disease course and with longer duration of immune-suppression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  2. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498.

    Article  CAS  PubMed  Google Scholar 

  3. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429.

    Article  CAS  PubMed  Google Scholar 

  4. Butcher BW, Collins Jr RH . The graft-versus-lymphoma effect: clinical review and future opportunities. Bone Marrow Transplant 2005; 36: 1–17.

    Article  CAS  PubMed  Google Scholar 

  5. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310–4316.

    Article  CAS  PubMed  Google Scholar 

  6. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91: 1178–1184.

    CAS  PubMed  Google Scholar 

  7. Jones RJ, Ambinder RF, Piantadosi S, Santos GW . Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653.

    CAS  PubMed  Google Scholar 

  8. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18–29.

    Article  CAS  PubMed  Google Scholar 

  9. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R . Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021–1028.

    Article  CAS  PubMed  Google Scholar 

  10. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    Article  CAS  PubMed  Google Scholar 

  11. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419–2423.

    Article  PubMed  Google Scholar 

  12. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535–3542.

    Article  CAS  PubMed  Google Scholar 

  13. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865–3871.

    Article  CAS  PubMed  Google Scholar 

  14. Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C et al. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11: 593–599.

    Article  PubMed  Google Scholar 

  15. Gopal AK, Pagel JM, Rajendran JG, Maloney DG, Appelbaum FR, Sorror ML et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant 2006; 12: 697–702.

    Article  CAS  PubMed  Google Scholar 

  16. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993–2003.

    Article  PubMed  Google Scholar 

  17. Cheson BD . Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101: 391–398.

    Article  CAS  PubMed  Google Scholar 

  18. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219–1224.

    Article  CAS  PubMed  Google Scholar 

  19. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461–467.

    Article  CAS  PubMed  Google Scholar 

  20. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896–2902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007; 35: 534–540.

    Article  CAS  PubMed  Google Scholar 

  22. Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or=60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007; 25: 1396–1402.

    Article  PubMed  Google Scholar 

  23. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assos 1958; 53: 457–481.

    Article  Google Scholar 

  24. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  PubMed  Google Scholar 

  25. Shimoni A, Hardan I, Shem-Tov N, Yerushalmi R, Bar-Natan M, Tsolakis F et al. Comparison between two reduced-intensity conditioning regimens prior to allogeneic stem cell transplantation: Fludarabine and melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine and busulfan (abstract). Blood 2006; 108 (Suppl 1): 835a (abstract 2947).

    Google Scholar 

  26. Knox SJ, Levy R, Miller RA, Uhland W, Schiele J, Ruehl W et al. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 1990; 50: 4935–4940.

    CAS  PubMed  Google Scholar 

  27. Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006; 107: 2184–2191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003; 32: 549–556.

    Article  CAS  PubMed  Google Scholar 

  29. Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I–II study. Blood 2001; 98: 565–572.

    Article  CAS  PubMed  Google Scholar 

  30. Bethge WA, Wilbur DS, Sandmaier BM . Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation. Leuk Lymphoma 2006; 47: 1205–1214.

    Article  CAS  PubMed  Google Scholar 

  31. Gopal AK, Rajendran JG, Pagel JM, Guthrie KA, Maloney DG, Appelbaum FR et al. A phase II trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL). Blood 2006; 108 (Suppl 1): 98a (abstract 316).

    Google Scholar 

  32. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L et al. Efficacy and Safety of Yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL). Blood 2006; 108 (Suppl 1): 98a (abstract 315).

    Google Scholar 

  33. Fietz T, Uharek L, Gentilini C, Muessig A, Rieger K, Marinets O et al. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 2006; 47: 59–63.

    Article  CAS  PubMed  Google Scholar 

  34. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804–1810.

    Article  CAS  PubMed  Google Scholar 

  35. Shimoni A, Hardan I, Avigdor A, Yeshurum M, Raananai P, Ben-Bassat I et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003; 122: 457–464.

    Article  CAS  PubMed  Google Scholar 

  36. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756–762.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Antin JH, Ferrara JL . Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964–2968.

    CAS  PubMed  Google Scholar 

  38. Johansson JE, Brune M, Ekman T . The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplant 2001; 28: 737–742.

    Article  CAS  PubMed  Google Scholar 

  39. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.

    Article  CAS  PubMed  Google Scholar 

  40. Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997; 97: 466–473.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel

    A Shimoni, I Hardan, N Shem-Tov, A Rand, R Yerushalmi, A Avigdor, I Ben-Bassat & A Nagler

  2. The Department of Nuclear Medicine, Chaim Sheba Medical Center, Tel-Hashomer, Israel

    S T Zwas & Y Oksman

Authors
  1. A Shimoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S T Zwas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Oksman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Hardan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Shem-Tov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Rand
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Yerushalmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Avigdor
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I Ben-Bassat
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Shimoni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shimoni, A., Zwas, S., Oksman, Y. et al. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant 41, 355–361 (2008). https://doi.org/10.1038/sj.bmt.1705919

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705919

Keywords

This article is cited by

Search

Advanced search

Quick links